Application of loperamide in reversing 5-fluorouracil resistance in colorectal cancer

Through the combined treatment of loperamide and 5-FU, the sensitivity of colorectal cancer cells to 5-FU is improved, the proliferation and migration ability of drug-resistant cells is inhibited, and the problem of resistance to 5-FU in patients with colorectal cancer is solved. , achieving more effective therapeutic effects.

CN118286219BActive Publication Date: 2024-11-15HEFEI YIFAN BIOLOGICAL PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410441788.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-12
Publication Date
2024-11-15
Estimated Expiration
2044-04-12

AI Technical Summary

Technical Problem

Resistance to 5-fluorouracil (5-FU) in patients with colorectal cancer leads to poor treatment effects, and the prior art lacks effective methods to reverse drug resistance.

Method used

Loperamide (LOP) inhibits the proliferation and migration ability of drug-resistant cells by increasing the IC50 value of 5-FU, and interferes with the occurrence of 5-FU resistance by promoting the occurrence of cellular autophagy, as combined with 5-FU Treatment options.

Benefits of technology

LOP significantly improves the sensitivity of colorectal cancer cells to 5-FU, inhibits the proliferation and malignant transformation of drug-resistant cells, delays the tumor progression, and provides an effective treatment plan to reverse drug resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118286219B_ABST
    Figure CN118286219B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedical technology, specifically, it relates to the application of loperamide in reversing the drug resistance of 5-fluorouracil in colorectal cancer, the application is for non-therapeutic purposes, and optionally, the content of loperamide is 20 μM; the present invention has found that for 5-FU-resistant cells of colorectal cancer, LOP can quickly increase the IC50 of 5-FU, effectively inhibit the proliferation ratio, clone formation and cell migration ability of drug-resistant cells, and the exploration of its molecular mechanism shows that LOP can promote cell autophagy, and may intervene in the occurrence of 5-FU resistance by inducing autophagy-apoptosis imbalance. Since LOP is also commonly used for diarrhea caused by chemotherapy in tumor patients, it can also play a role in reversing the drug resistance of 5-FU in colorectal cancer cells. Then for drug-resistant patients, combined LOP treatment will be a more effective treatment plan. The present invention has found the application of LOP in patients with 5-FU resistance to colorectal cancer, and its clinical value is great.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, and in particular, relates to the application of loperamide in reversing 5-fluorouracil resistance in colorectal cancer. Background Art

[0002] Among the chemotherapy molecules used in the treatment of colorectal cancer, the most commonly used is 5-fluorouracil (5-FU), a synthetic fluoropyrimidine analog that treats more than 2 million cancer patients worldwide each year. In addition to its widespread use in the treatment of colorectal cancer, 5-FU is also widely used in the treatment of pancreatic cancer, gastric cancer, esophageal cancer, breast cancer, and head and neck tumors. 5-FU belongs to the class of anticancer drugs called antimetabolites, and its activity is through intracellular conversion to active metabolites that interfere with thymine biosynthesis and affect DNA and RNA-mediated processes. However, due to the emergence of drug resistance, the treatment effect is poor. In recent years, research on the mechanism of 5-FU resistance has received extensive attention. It has been determined that 5-FU resistance may be caused by a variety of reasons: (1) reduced intracellular FdUMP levels; (2) increased activity of the target enzyme TS; and (3) dysregulation of the balance between autophagy and apoptosis in favor of cell survival. To overcome 5-FU resistance, researchers are looking for new treatments. For example, combination therapy, targeted therapy, and immunotherapy are all being studied in clinical trials.

[0003] In summary, finding new drugs and intervention targets that can reverse 5-FU resistance is expected to bring new breakthroughs in the treatment of colorectal cancer.

[0004] 5-Fluorouracil (5-FU) is a core component in the treatment of colorectal cancer. In patients with stage III and high-risk stage II CRC, the use of 5-FU-based chemotherapy combinations can reduce the risk of disease recurrence. Although current 5-FU-based chemotherapy regimens have significantly improved the survival of patients with metastatic colorectal cancer (approximately 20 months), the 5-year survival rate remains low, less than 14%, indicating an urgent need to understand the mechanistic basis of resistance and develop new strategies to more thoroughly eradicate metastatic disease. Intrinsic or acquired resistance remains the main cause of treatment failure in patients with metastatic cancer.

[0005] Loperamide (LOP) is a commonly used drug for treating diarrhea in clinical practice, and its safety has been proven. At a safe dose, it has little toxicity and side effects on the human body and no obvious adverse reactions.

[0006] With regard to the existing technology, Gebbia compared the efficacy of loperamide with octreotide in the treatment of 5-FU-related diarrhea. Among 20 patients who used octreotide, 16 had their diarrhea symptoms controlled after 4 days, while only 4 patients who used loperamide had their diarrhea symptoms controlled. Similar results were obtained in other studies on irinotecan-related diarrhea. The diarrhea relief rate of octreotide was higher than that of loperamide (see Clinical and Experimental Study on the Treatment of Postoperative Diarrhea after Colon Cancer with Tongxie Yaofang, Chengdu University of Traditional Chinese Medicine, 2017).

[0007] In the prior art, Liu Danning et al. studied the effects and mechanism of total flavonoids of Citrus aurantium on 5-fluorouracil (5-FU)-induced intestinal mucosal inflammation and intestinal flora. Methods Male Kunming mice were randomly divided into a control group, a model group, and low, medium, and high dose groups of total flavonoids of Citrus aurantium and loperamide, and an intestinal mucosal inflammation model was induced by ip 5-FU. Results: Compared with the model group, the body weight and food intake of mice in the total flavonoids of Citrus aurantium group increased, the water intake decreased, the diarrhea score decreased, the thymus index and spleen index increased significantly, the colon tissue damage was alleviated, the colon length and crypt depth increased significantly, the levels of proinflammatory cytokines IL-6, IL-1β and TNF-α in colon tissue decreased significantly, the activities of SOD and GSH-Px increased significantly, and the MDA level decreased significantly. The results of 16SrRNA gene sequencing showed that the diversity and abundance of intestinal flora of mice in the model group decreased, while the diversity and abundance of intestinal flora of mice in the total flavonoids of Citrus aurantium group increased. Conclusion: Total flavonoids of Citrus aurantium can effectively improve intestinal mucositis in mice induced by 5-FU, and its mechanism may be related to antioxidant, anti-inflammatory, and regulation of intestinal flora (see Effects of total flavonoids of Citrus aurantium on intestinal flora imbalance in mice with intestinal mucositis induced by 5-fluorouracil, "Chinese Herbal Medicine", 2021).

[0008] The above-mentioned prior art does not record the combined use of 5-FU and LOP in the treatment of colorectal cancer; however, our previous studies have found that for colorectal cancer 5-FU-resistant cells, LOP can quickly increase the IC50 of 5-FU and effectively inhibit the proliferation rate, clone formation and cell migration ability of resistant cells. The exploration of its molecular mechanism shows that LOP can promote cell autophagy and may intervene in the occurrence of 5-FU resistance by inducing autophagy-apoptosis imbalance. Since LOP is also commonly used for chemotherapy-induced diarrhea in cancer patients, if it can also reverse the 5-FU resistance of colorectal cancer cells, then combined LOP treatment will be a more effective treatment option for resistant patients. Summary of the invention

[0009] The present invention firstly provides the application of loperamide in reversing the 5-fluorouracil resistance of colorectal cancer, and the application is for non-therapeutic purpose.

[0010] Preferably, the subject of reversal is a human suffering from colorectal cancer, an animal suffering from colorectal cancer, or a colorectal cancer 5-fluorouracil-resistant cell line.

[0011] Preferably, the cell line is HCT-8R.

[0012] Preferably, the content of loperamide is 20 μM.

[0013] The present invention also provides the use of loperamide in preparing a drug for reversing the 5-fluorouracil resistance of colorectal cancer.

[0014] Preferably, the subject of reversal is a human suffering from colorectal cancer, an animal suffering from colorectal cancer, or a colorectal cancer 5-fluorouracil-resistant cell line.

[0015] Preferably, the cell line is HCT-8R.

[0016] Preferably, the content of loperamide is 20 μM.

[0017] The present invention also provides a pharmaceutical composition for treating colorectal cancer, wherein the kit comprises loperamide and 5-fluorouracil, and optionally, the content of loperamide is 20 μM.

[0018] Finally, the present invention provides an application of the above-mentioned pharmaceutical composition in preparing a drug for treating colorectal cancer.

[0019] Compared with the prior art, the present invention has at least the following beneficial effects:

[0020] The present invention has found that for 5-FU-resistant cells of colorectal cancer, LOP can quickly increase the IC50 of 5-FU and effectively inhibit the proliferation rate, clone formation and cell migration ability of resistant cells. The exploration of its molecular mechanism shows that LOP can promote cell autophagy and may intervene in the occurrence of 5-FU resistance by inducing autophagy-apoptosis imbalance. Since LOP is also commonly used for diarrhea caused by chemotherapy in cancer patients, it can also reverse the 5-FU resistance of colorectal cancer cells. Therefore, for resistant patients, combined LOP treatment will be a more effective treatment plan. The present invention has discovered the use of LOP in patients with 5-FU resistance to colorectal cancer, and its clinical value is extremely high. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Loperamide increases the sensitivity of colorectal cancer resistant cells to 5-FU;

[0022] Figure 2 Loperamide inhibits the proliferation of drug-resistant colorectal cancer cells;

[0023] Figure 3Loperamide inhibits the malignant transformation of drug-resistant colorectal cancer cells; (A) Loperamide inhibits the cloning of drug-resistant colorectal cancer cells; (B) Loperamide inhibits the migration ability of drug-resistant colorectal cancer cells;

[0024] Figure 4 Loperamide activates autophagy in drug-resistant colorectal cancer cells;

[0025] Figure 5 Animal experiment results. DETAILED DESCRIPTION

[0026] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0027] Example 1: Loperamide was administered to colorectal cancer resistant cell lines to detect changes in 5-FU proliferation inhibition rate

[0028] CCK8 cell proliferation inhibition rate detection

[0029] The drug-resistant human colorectal cancer cell line HCT-8R was purchased from Shanghai Meiyan Company and cultured in a 37°C, 5% CO2 incubator in DMEM supplemented with 10% fetal bovine serum.

[0030] (1) The colorectal cancer 5-FU-resistant cell line HCT-8R was divided into a treatment group and a control group. The control group was treated with DMSO, and the treatment group was given 20 μM LOP and incubated with different concentrations of 5-FU (0, 20, 40, 60, 80 μg / μl) for 24 hours. Each group of cells was seeded in a 96-well plate, with at least 4 replicate wells in each group, and the experiment was repeated at least 3 times.

[0031] (2) After 24 hours, discard the old culture medium, add a mixture of CCK8 stock solution: DMEM culture medium (10 μL:100 μL), and culture in a 37°C, 5% CO2 cell culture incubator for 2 hours;

[0032] (3) After 2 hours, the 96-well plate was placed in a multifunctional microplate reader (Molecular Devices, USA), and the values ​​were detected at a wavelength of 450 nm and saved for subsequent calculation of the inhibition rate. Graphpadprism 9.0 was used to plot the inhibition rate.

[0033] The results showed that 20 μM LOP could effectively increase the sensitivity of colorectal cancer resistant cells HCT-8R to 5-FU and reverse the occurrence of 5-FU resistance ( Figure 1 ).

[0034] Example 2 Administration of loperamide to detect the proliferation level of colorectal cancer resistant cells

[0035] EdU DNA cell proliferation assay

[0036] (1) The colorectal cancer 5-FU-resistant cell line HCT-8R was divided into an untreated group, a 5-FU group, a DMSO group, and a LOP group. Each group of cells was inoculated in a 24-well plate, and the cell concentration was adjusted to 20,000 cells / well until the cells were 60-70% confluent. No drug was added to the untreated group, and 40 μg / μl 5-FU was added to the other three groups. The DMSO group used 20 μM DMSO, and the LOP group was given 20 μM LOP to treat the cells for 24 hours.

[0037] (2) Discard the culture medium and add 200 μL of EdU:FBS-free fresh DMEM (1:100) mixture, and culture in a cell culture incubator overnight;

[0038] (3) Discard the mixed solution, wash three times with PBS, and fix with 4% paraformaldehyde for 30 min;

[0039] (4) Discard paraformaldehyde, wash three times with PBS, add 100 μL of 2 mg / mL glycine, incubate at room temperature for 5 min, and wash three times with 3% BSA; remove the washing solution, add 100 μL of 0.5% TritonX-100, and incubate at room temperature for 20 min;

[0040] (5) Prepare EdU reaction mixture according to the Cell-Light EdU DNA Cell Proliferation Kit, remove TritonX-100, wash three times with 3% BSA; add 200 μL EdU reaction solution, incubate on a shaker in the dark for 30 min, and wash three times with 3% BSA, 5 min / time;

[0041] (6) Add DAPI, incubate in dark for 10 min, and wash three times with 3% BSA, 5 min / time for the first two times and 10 min for the last time;

[0042] (7) Observe and take pictures under an inverted fluorescence microscope (Leica, Germany).

[0043] The results showed that 5-FU administration did not effectively inhibit cell proliferation in drug-resistant cells, indicating that the cell line did have 5-FU resistance. The EdU uptake rate of cells in the LOP administration group was significantly reduced, and the number of proliferating cells was significantly reduced ( Figure 2 ). This indicates that loperamide can specifically inhibit the proliferation of colorectal cancer resistant cells and has a good effect of reversing drug resistance.

[0044] Example 3 Confirmation that loperamide inhibits malignant transformation of colorectal cancer resistant cells

[0045] Colony formation assay

[0046] (1) The 5-FU-resistant colorectal cancer cell line HCT-8R was divided into untreated group, 5-FU group, DMSO group and LOP group. The cells in each group were seeded in a 6-well plate, the cell concentration was adjusted to 1000 cells / well, and the cells were spread in the 6-well plate.

[0047] (2) After about 3 days, the cells aggregated into small clusters. No drug was added to the untreated group, while 40 μg / μl 5-FU was added to the other three groups. The DMSO group was treated with 20 μM DMSO, and the LOP group was co-treated with 20 μM LOP. New culture medium and drugs were replaced every 3 days.

[0048] (3) About 6-8 days after administration, observe under a microscope, and when cells are obviously aggregated, discard the culture medium and wash with PBS three times;

[0049] (4) Fix with 4% paraformaldehyde for 30 min, wash three times with PBS, stain with crystal violet for 30 min, wash cells several times with PBS, dry, and photograph.

[0050] Cell scratch assay

[0051] (1) The colorectal cancer 5-FU-resistant cell line HCT-8R was divided into untreated group, 5-FU group, DMSO group and LOP group. Cells in the exponential growth phase were obtained, digested with trypsin to form a single cell suspension, and evenly inoculated into a 6-well cell culture plate;

[0052] (2) The cells were cultured in a 37°C, 5% CO2 incubator for 24 hours, and the cell fusion rate reached 100% after 24 hours;

[0053] (3) Use a 200 μL pipette tip to vertically scratch the cells, gently rinse the cells with PBS three times, wash the scratched cells, and add DMEM medium containing 2% FBS;

[0054] (4) Take photos under an inverted microscope, adjust the cell culture plate to ensure that the scratch is centered and vertical, add the corresponding drug to treat the cells 24 hours later, and take photos under a microscope. Use Image J software to process the healing rate of the pictures.

[0055] Since clone formation and cell migration ability are important indicators of cell invasion and metastasis, we used clone formation and cell scratch assays to detect the effect of loperamide on colorectal cancer resistant cells. The results showed that loperamide can effectively inhibit the clone formation of HCT-8R ( Figure 3 A) and cell migration levels ( Figure 3 B). The above results indicate that LOP can effectively inhibit the malignant phenotype of colorectal cancer resistant cells.

[0056] Example 4 Exploring the molecular mechanism of loperamide in reversing 5-FU resistance in colorectal cancer

[0057] Western-blot

[0058] (1) Use RIPA lysis buffer to extract whole cell lysate, and use BCA protein assay to determine and adjust the protein concentration of each sample to be consistent. Add 5× SDS loading buffer to dilute to 1×, place in a 99℃ metal bath for 10 minutes, and then place the protein sample on ice for later use.

[0059] (2) Electrophoresis: Place the prepared electrophoresis gel in the electrophoresis tank. Add 1× SDS electrophoresis buffer. Load the protein marker and protein into the wells of the electrophoresis gel. Perform concentration electrophoresis at 80V. Perform separation electrophoresis at 120V.

[0060] (3) Transfer: After electrophoresis, cut the protein gel into appropriate sizes according to the molecular weight of the target protein. Activate the PVDF membrane with methanol in advance. Place the protein gel, cotton pad, and filter paper in the transfer clip in order and gently transfer them into the transfer clip. Be careful to avoid bubbles. Place the transfer clip into the transfer tank and add 1× transfer solution at 300 mA for 1.5 h.

[0061] (4) Blocking: Prepare a blocking solution with 5% skim milk and 1× TBST, immerse the PVDF membrane in it, and block slowly on a shaker for 2 h.

[0062] (5) Antibody incubation: The target proteins were incubated with primary antibodies, Beclin (11306-1-AP, Proteintech Group), β-actin (66009-1-Ig, Proteintech Group), and LC3β (3868, Cell Signaling Technology), and incubated overnight in a shaker at 4°C. The next day, the cells were washed with TBST and incubated with the corresponding secondary antibodies for 2 h.

[0063] (6) Development: Mix solution A and solution B in the ECL Western blot detection kit (SQ203, Omni-ECL) in proportion and drop them on the corresponding PVDF membrane area for exposure and development.

[0064] Autophagosome detection

[0065] (1) Cell transfection: The colorectal cancer 5-FU-resistant cell line HCT-8R was divided into GFP group, LC3 group, DMSO group and LOP group. After the growth density of adherent cells in the logarithmic growth phase reached about 70%, the new culture medium was replaced. The GFP group was transfected with an empty GFP plasmid, and the other three groups were transfected with a GFP-LC3 plasmid. The plasmid to be transfected and the transfection reagents Lipofectamine 8000 and opti-MEM were mixed in the corresponding proportions and added to the culture medium, and the mixture was mixed and cultured for 48 hours.

[0066] (2) The GFP group was not treated with drugs, while the other three groups were treated with 40 μg / μl 5-FU. The DMSO group was treated with 20 μM DMSO, and the LOP group was treated with 20 μM LOP for 24 h.

[0067] (3) Discard the culture medium, wash three times with PBS, and fix with 4% paraformaldehyde for 30 min;

[0068] (4) Discard paraformaldehyde, wash three times with PBS, add 100 μL 0.5% TritonX-100, and incubate at room temperature for 20 min;

[0069] (5) Add DAPI, incubate in dark for 10 min, and wash three times with 3% BSA, 5 min / time for the first two times and 10 min for the last time;

[0070] (6) Observe and take photos under an inverted fluorescence microscope (Leica, Germany).

[0071] Since the imbalance between autophagy and apoptosis is one of the main mechanisms of 5-FU resistance, previous studies have also found that LOP can induce cell autophagy. Therefore, we tested the autophagy level of colorectal cancer resistant cells after LOP administration, and found that LOP can cause upregulation of autophagy-related protein expression and induce the formation of cell autophagosomes ( Figure 4 The above results indicate that LOP may effectively reverse the occurrence of 5-FU resistance in colorectal cancer cells by activating cell autophagy and interfering with the imbalance of autophagy-apoptosis.

[0072] Example 5 Loperamide delays the tumorigenesis process of colorectal cancer resistant cells in vivo

[0073] Nude mouse transplant tumor experiment

[0074] (1) A large number of amplified 5-FU-resistant colorectal cancer cell lines HCT-8R (2×10 7 cells / mL) were inoculated subcutaneously in nude mice, and the growth status of the nude mice was observed.

[0075] (2) After the tumor grew to a palpable size (about 1 week), the nude mice were randomly divided into two groups. The control group was intraperitoneally injected with normal saline, and the treatment group was intraperitoneally injected with LOP (2 mg / kg / day). The body weight of the nude mice and the size of the tumor tissue were recorded every 3-5 days.

[0076] (3) Intraperitoneal injection of 5-FU was performed for 7 days, and the growth status of the mice was observed.

[0077] (4) After 3-4 weeks, the nude mice were killed and the tumor tissue was weighed.

[0078] The results showed that the size and weight of the tumors in the LOP group were reduced. LOP could effectively reduce the rate of tumor formation in HCT-8R in vivo and enhance the inhibitory effect of 5-FU on drug-resistant cells ( Figure 5 ).

[0079] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. The application of loperamide in reversing 5-fluorouracil resistance in colorectal cancer in vitro. It is characterized in that The use is for non-therapeutic purposes.

2. The use according to claim 1, It is characterized in that The object of reversal is a colorectal cancer 5-fluorouracil-resistant cell line.

3. The use according to claim 2, It is characterized in that The cell line is HCT-8R.

4. The use according to any one of claims 1 to 3, It is characterized in that The content of loperamide is 20 μM.

5. The use of loperamide in the preparation of drugs for reversing 5-fluorouracil resistance in colorectal cancer.

6. The use according to claim 5, It is characterized in that The object of reversal is a human suffering from colorectal cancer, an animal suffering from colorectal cancer or a colorectal cancer 5-fluorouracil-resistant cell line.

7. The use according to claim 5, It is characterized in that The cell line is HCT-8R.

8. The use according to any one of claims 5 to 7, It is characterized in that The content of loperamide is 20 μM.